SWOG clinical trial number
SWOG-9208
Health Status and Quality of Life (QL) in Patients with Early Stage Hodgkin's Disease: A companion study to SWOG-9133, Ancillary
Closed
Phase
Published
Abbreviated Title
Quality of Life Companion study - Hodgkin's
Activated
04/15/1994
Closed
04/24/2000
Research committees
Lymphoma
Eligibility Criteria Expand/Collapse
Patients entered on SWOG-9133; Pts. able to read and understand English.
Publication Information Expand/Collapse
2017
2007
Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions
PMid: PMID17991922
2004
Predictors of vitality (energy/fatigue) in early stage hodgkin's disease (HD): results from Southwest Oncology Group (SWOG) study 9133
2003
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group study 9133
2000
Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase